C-reactive protein and lipoprotein-a as markers of coronary heart disease in polycystic ovary syndrome;Polikistik over sendromlu hastalarda koroner kalp hastalıklarının belirteci olarak c-reaktif protein ve lipoprotein-a bakılması

Journal of the Turkish German Gynecology Association

Volumn 13, Issue 4, 2012, Pages 227-232

  Güdücü, Nilgün ^a   Işçi, Herman ^a   Yiǧiter, Alin Başgül ^a   Dünder, Ilkkan ^a  

^a ISTANBUL BILIM UNIVERSITY   (Turkey)

Author keywords

Coronary heart disease; CRP; Lipoprotein a; Obesity; Polycystic ovary syndrome

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROCORTISONE; INSULIN; LIPOPROTEIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSULIN BLOOD LEVEL; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84872556000     PISSN: 13090399     EISSN: 13090380     Source Type: Journal    
DOI: 10.5152/jtgga.2012.35     Document Type: Article

References (27)

1. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000; 132: 989-93.
2. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853-61. [CrossRef]
3. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 1929-35. [CrossRef]
4. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN, et al. Prevalence and predictors of metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 48-53. [CrossRef]
5. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003; 52: 908-15. [CrossRef]
6. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-national Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93: 1276-84. [CrossRef]
7. Scanu AM. Lipoprotein (a). A genetic risk factor for premature coronary heart disease. JAMA 1992; 267: 3326-9. [CrossRef]
8. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004; 89: 2160-5. [CrossRef]
9. Berneis K, Rizzo M, Hersberger M, Rini GB, Di Fede G, Pepe I, et al. Atherogenic forms of dyslipidemia in women with polycystic ovary syndrome. Int J Clin Pract 2009; 63: 56-62. [CrossRef]
10. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25. [CrossRef]
11. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and other markers of inflammation in the prediction of first cardiovascular event. N Engl J Med 2002; 347: 1557-65. [CrossRef]
12. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med. 2002; 252: 283-94. [CrossRef]
13. Kelly C, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86: 2453-5. [CrossRef]
14. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003; 80: 123-7. [CrossRef]
15. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004; 89: 5592-96. [CrossRef]
16. Gen R, Akbay E, Muslu N, Sezer K, Cayan F. Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance. Gynecol Endocrinol 2009; 25: 241-5. [CrossRef]
17. Möhlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004; 150: 525-32. [CrossRef]
18. Tosi F, Dorizzi R, Castello R, Maffeis C, Spiazzi G, Zoppini G, et al. Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome. Eur J Endocrinol 2009; 161: 737-45. [CrossRef]
19. Bozbaş H, Yildirir A, Pirat B, Eroǧlu S, Korkmaz ME, Atar I, et al. Increased lipoprotein(a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis? The Anatolian Journal of Cardiology 2008; 8: 111-5.
20. Onat A, Hergenç G, Ozhan H, Kaya Z, Bulur S, Ayhan E, et al. Lipoprotein(a) is associated with coronary heart disease independent of metabolic syndrome. Coron Artery Dis 2008; 19: 125-31. [CrossRef]
21. Starkman HS, Cable G, Hala V, Hecht H, Donnelly CM. Delineation of prevalence and risk factors for early artery disease by electron beam computed tomography in young adults with type 1 diabetes. Diabetes Care 2003; 26: 433-6. [CrossRef]
22. Qasim AN, Martin SS, Mehta NN, Wolfe ML, Park J, Shcwartz S, et al. Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women. Int J Cardiol 2011; 150: 17-21. [CrossRef]
23. Yilmaz M, Biri A, Bukan N, Karakoç A, Sancak B, Toruner F, et al. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol 2005; 20: 258-63. [CrossRef]
24. Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, et al. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod 2009; 24: 2286-92. [CrossRef]
25. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-74. [CrossRef]
26. Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine 2006; 30: 13-7. [CrossRef]
27. Talbott EO, Zborowski JV, Sutton-Tyrrell K, McHugh-Pemu KP, Guzick DS. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001; 28: 111-33. [CrossRef]